Paper
0
Optimal Systemic Treatment and Real-World Clinical Application of ctDNA in Patients with Metastatic HER2-Mutant Lung Cancer
Authors
Si‐Yang Liu,Tatiana Erazo
Justin Jee,Andrea Arfé,Avantika Gupta,Luke Pike,Fernando Santini,Bobby Daly,Adam Schoenfeld,Jordan Eichholz,Kaylie Johnson,Andrés Martinez,Jane Sui,Nadeem Riaz,Jason Chang,Soo‐Ryum Yang,William Travis,Maria Arcila,Jiannan Guo,Éric Gagné,Kavita Garg,Frederick Baehner,Nancy Lee,Alexander Drilon,Mark Kris,Howard Scher,Pedram Razavi,Daniel Gomez,David Jones,Charles Rudin,Sarat Chandarlapaty,James Isbell
+30 authors
,Bob LiJournal
Published
Aug 14, 2024
Show more
Save
Tip0
TipSave
Abstract
No definitive answers currently exist regarding optimal first-line therapy for HER2-mutant NSCLC. Access to rapid tissue sequencing is a major barrier to precision drug development in the first-line setting. ctDNA analysis has the potential to overcome these obstacles and guide treatment.
Paper PDF
This paper's license is marked as closed access or non-commercial and cannot be viewed on ResearchHub. Visit the paper's external site.